Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) traded up 5.7% during trading on Friday . The stock traded as high as $3.41 and last traded at $3.35, with a volume of 103,137 shares trading hands. The stock had previously closed at $3.17.

Several analysts have recently commented on the stock. Cowen and Company reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 10th. Chardan Capital dropped their price objective on shares of Dicerna Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a report on Thursday, June 30th. Stifel Nicolaus dropped their price objective on shares of Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating on the stock in a report on Thursday, June 30th. Leerink Swann reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 10th. Finally, Zacks Investment Research raised shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a report on Thursday, May 12th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Dicerna Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $11.95.

The stock has a 50 day moving average price of $3.42 and a 200 day moving average price of $5.25. The stock’s market cap is $69.22 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.10. On average, analysts anticipate that Dicerna Pharmaceuticals Inc. will post ($3.34) EPS for the current fiscal year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.